A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Abstract Purpose: Uveal melanoma is a rare and aggressive subset of melanoma that is minimally responsive to traditional therapies. Greater than 80% of uveal melanomas have a mutation in GNAQ or GNA11 which lead to downstream signaling through the MAPK pathway. Ulixertinib (BVD-523) is a potent and...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | eaŋgalasgiella |
| Almmustuhtton: |
2024
|
| Liŋkkat: | https://doi.org/10.1158/2767-9764.crc-24-0036 https://aacrjournals.org/cancerrescommun/article-pdf/doi/10.1158/2767-9764.CRC-24-0036/3448399/crc-24-0036.pdf |
| Fáddágilkorat: |
Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|